{"id":87961,"date":"2026-05-15T11:21:18","date_gmt":"2026-05-15T05:51:18","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=87961"},"modified":"2026-05-15T13:02:53","modified_gmt":"2026-05-15T07:32:53","slug":"sun-pharmaceutical-industries-analyst-review-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-industries-analyst-review-2026\/","title":{"rendered":"Sun Pharmaceutical Industries (SUNPHARMA) Stock Analyst Review May 2026"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p>This <strong><a href=\"https:\/\/univest.in\/user\/stocks\/sunpharma\/sun-pharmaceutical-industries-ltd-share-price-today\">Sun Pharmaceutical Industries<\/a> analyst review<\/strong> for May 2026 assesses SUNPHARMA at approximately Rs 1,720. Sun Pharmaceutical Industries (NSE: SUNPHARMA) is India&#8217;s largest pharmaceutical company and fifth largest specialty generic pharma company globally, with a market capitalisation of Rs 4,13,000 crore. This <strong>Sun Pharmaceutical Industries analyst review<\/strong> focuses on the US specialty drug portfolio, global branded generics business, and the specialty dermatology pipeline as the primary value creation drivers.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-industries-analyst-review-2026\/#Sun_Pharmaceutical_Industries_Company_Snapshot_May_2026\" title=\"Sun Pharmaceutical Industries Company Snapshot May 2026\">Sun Pharmaceutical Industries Company Snapshot May 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-industries-analyst-review-2026\/#Latest_Results_and_Business_Performance\" title=\"Latest Results and Business Performance\">Latest Results and Business Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-industries-analyst-review-2026\/#Segment_and_Business_Analysis_in_This_Sun_Pharmaceutical_Industries_Analyst_Review\" title=\"Segment and Business Analysis in This Sun Pharmaceutical Industries Analyst Review\">Segment and Business Analysis in This Sun Pharmaceutical Industries Analyst Review<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-industries-analyst-review-2026\/#US_Specialty_Business\" title=\"US Specialty Business\">US Specialty Business<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-industries-analyst-review-2026\/#India_Branded_Generics\" title=\"India Branded Generics\">India Branded Generics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-industries-analyst-review-2026\/#Emerging_Markets_and_Rest_of_World\" title=\"Emerging Markets and Rest of World\">Emerging Markets and Rest of World<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-industries-analyst-review-2026\/#Valuation_and_Analyst_Price_Targets\" title=\"Valuation and Analyst Price Targets\">Valuation and Analyst Price Targets<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-industries-analyst-review-2026\/#Key_Catalysts_for_Sun_Pharmaceutical_Industries_in_FY27\" title=\"Key Catalysts for Sun Pharmaceutical Industries in FY27\">Key Catalysts for Sun Pharmaceutical Industries in FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-industries-analyst-review-2026\/#Key_Risks_in_This_Sun_Pharmaceutical_Industries_Analyst_Review\" title=\"Key Risks in This Sun Pharmaceutical Industries Analyst Review\">Key Risks in This Sun Pharmaceutical Industries Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-industries-analyst-review-2026\/#Conclusion_Sun_Pharmaceutical_Industries_Analyst_Review_Verdict\" title=\"Conclusion: Sun Pharmaceutical Industries Analyst Review Verdict\">Conclusion: Sun Pharmaceutical Industries Analyst Review Verdict<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-industries-analyst-review-2026\/#Frequently_Asked_Questions_on_Sun_Pharmaceutical_Industries_Analyst_Review_2026\" title=\"Frequently Asked Questions on Sun Pharmaceutical Industries Analyst Review 2026\">Frequently Asked Questions on Sun Pharmaceutical Industries Analyst Review 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-industries-analyst-review-2026\/#What_is_the_analyst_target_for_Sun_Pharma_in_2026\" title=\"What is the analyst target for Sun Pharma in 2026?\">What is the analyst target for Sun Pharma in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-industries-analyst-review-2026\/#What_is_Sun_Pharmas_US_specialty_business\" title=\"What is Sun Pharma&#8217;s US specialty business?\">What is Sun Pharma&#8217;s US specialty business?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-industries-analyst-review-2026\/#Is_Sun_Pharma_a_good_buy_in_2026\" title=\"Is Sun Pharma a good buy in 2026?\">Is Sun Pharma a good buy in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-industries-analyst-review-2026\/#What_is_Sun_Pharmas_India_business_growth\" title=\"What is Sun Pharma&#8217;s India business growth?\">What is Sun Pharma&#8217;s India business growth?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharmaceutical-industries-analyst-review-2026\/#What_are_the_key_US_FDA_risks\" title=\"What are the key US FDA risks?\">What are the key US FDA risks?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Sun_Pharmaceutical_Industries_Company_Snapshot_May_2026\"><\/span><strong>Sun Pharmaceutical Industries Company Snapshot May 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This <strong>Sun Pharmaceutical Industries analyst review<\/strong> is based on live market data as of May 2026, incorporating the latest quarterly results and analyst consensus targets for Sun Pharmaceutical Industries (NSE: SUNPHARMA), one of India&#8217;s largest companies in the Pharmaceuticals sector.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Parameter<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>SUNPHARMA<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Pharmaceuticals<\/td>\n<\/tr>\n<tr>\n<td>CMP (May 2026)<\/td>\n<td>Rs 1,720<\/td>\n<\/tr>\n<tr>\n<td>52 Week High<\/td>\n<td>Rs 1,968<\/td>\n<\/tr>\n<tr>\n<td>52 Week Low<\/td>\n<td>Rs 1,557<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 4,13,000 Crore<\/td>\n<\/tr>\n<tr>\n<td>Trailing P\/E<\/td>\n<td>36.50x<\/td>\n<\/tr>\n<tr>\n<td>Analyst Consensus Target<\/td>\n<td>Rs 2,050<\/td>\n<\/tr>\n<tr>\n<td>Bull Case Target<\/td>\n<td>Rs 2,300<\/td>\n<\/tr>\n<tr>\n<td>Bear Case Target<\/td>\n<td>Rs 1,450<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Latest_Results_and_Business_Performance\"><\/span><strong>Latest Results and Business Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Sun Pharma has been delivering consistent double-digit revenue growth driven by the US specialty business, India branded generics, and emerging markets. The US specialty segment including Ilumya (psoriasis), Cequa (dry eye), and the oncology portfolio generates EBITDA margins of 30 to 35 percent. Sun Pharma&#8217;s India business grows at 10 to 12 percent YoY through chronic therapy segments (cardiology, neurology, diabetes). This <strong>Sun Pharmaceutical Industries analyst review<\/strong> identifies specialty drug NDA filings and US FDA approvals as the key binary catalysts in FY27.<\/p>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Screen the best stocks on the Univest Screener.<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Segment_and_Business_Analysis_in_This_Sun_Pharmaceutical_Industries_Analyst_Review\"><\/span><strong>Segment and Business Analysis in This Sun Pharmaceutical Industries Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"US_Specialty_Business\"><\/span><strong>US Specialty Business<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The US specialty segment is the highest-margin and fastest-growing division. Ilumya (psoriasis), Cequa (dry eye disease), and oncology drugs drive premium royalty and branded revenues. This segment is the primary stock-level catalyst in this <strong>Sun Pharmaceutical Industries analyst review<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"India_Branded_Generics\"><\/span><strong>India Branded Generics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India contributes approximately 35 percent of consolidated revenue with branded generics across cardiology, neurology, psychiatry, and diabetes. Consistent market share gain at 10 to 12 percent YoY growth is a core strength in this <strong>Sun Pharmaceutical Industries analyst review<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Emerging_Markets_and_Rest_of_World\"><\/span><strong>Emerging Markets and Rest of World<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sun Pharma has a strong presence in Russia, Romania, and other emerging markets with branded generics offering higher-than-generic margins that support overall revenue mix per this <strong>Sun Pharmaceutical Industries analyst review<\/strong>.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Valuation_and_Analyst_Price_Targets\"><\/span><strong>Valuation and Analyst Price Targets<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At Rs 1,720, SUNPHARMA trades at 36.5x trailing P\/E, reflecting the market&#8217;s premium for its specialty drug pipeline. The consensus target of Rs 2,050 implies 19 percent upside. This <strong>Sun Pharmaceutical Industries analyst review<\/strong> notes that successful US specialty NDA approvals in FY27 could drive further re-rating toward the bull case of Rs 2,300.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Scenario<\/th>\n<th>Target Price<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 2,300<\/td>\n<\/tr>\n<tr>\n<td>Base Case (Consensus)<\/td>\n<td>Rs 2,050<\/td>\n<\/tr>\n<tr>\n<td>Bear Case<\/td>\n<td>Rs 1,450<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Screen the best stocks on the Univest Screener.<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Catalysts_for_Sun_Pharmaceutical_Industries_in_FY27\"><\/span><strong>Key Catalysts for Sun Pharmaceutical Industries in FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Key catalysts in this <strong>Sun Pharmaceutical Industries analyst review<\/strong> include new US specialty NDA approvals in dermatology and ophthalmology, Ilumya ARPU expansion as psoriasis market penetration grows, India business maintaining 10 to 12 percent growth, and resolution of any pending US FDA observations clearing the way for additional product launches.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_in_This_Sun_Pharmaceutical_Industries_Analyst_Review\"><\/span><strong>Key Risks in This Sun Pharmaceutical Industries Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Key risks in this <strong>Sun Pharmaceutical Industries analyst review<\/strong> include US FDA import alerts or Warning Letters at key manufacturing facilities, specialty drug pricing pressure from US payer negotiations and PBMs, generic erosion of key US products, and INR appreciation compressing export revenue in INR terms.<\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to get daily stock recommendations and expert research.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_Sun_Pharmaceutical_Industries_Analyst_Review_Verdict\"><\/span><strong>Conclusion: Sun Pharmaceutical Industries Analyst Review Verdict<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This <strong>Sun Pharmaceutical Industries analyst review<\/strong> concludes that SUNPHARMA at Rs 1,720 is a quality large-cap pharma holding with a best-in-class specialty drug pipeline, dominant India branded generics franchise, and global emerging market presence. The consensus Rs 2,050 target implies 19 percent upside per this <strong>Sun Pharmaceutical Industries analyst review<\/strong>. Always consult a SEBI-registered financial advisor before making any investment decisions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Sun_Pharmaceutical_Industries_Analyst_Review_2026\"><\/span><strong>Frequently Asked Questions on Sun Pharmaceutical Industries Analyst Review 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_analyst_target_for_Sun_Pharma_in_2026\"><\/span><strong>What is the analyst target for Sun Pharma in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The consensus target is approximately Rs 2,050, with a bull case of Rs 2,300. This <strong>Sun Pharmaceutical Industries analyst review<\/strong> notes majority Buy ratings among institutional analysts covering SUNPHARMA.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Sun_Pharmas_US_specialty_business\"><\/span><strong>What is Sun Pharma&#8217;s US specialty business?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The US specialty segment includes Ilumya (psoriasis), Cequa (dry eye), and oncology drugs. It is the highest-margin division and the primary stock-level catalyst in this <strong>Sun Pharmaceutical Industries analyst review<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Sun_Pharma_a_good_buy_in_2026\"><\/span><strong>Is Sun Pharma a good buy in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At 36.5x P\/E with specialty drug pipeline potential and 19 percent upside to consensus target, this <strong>Sun Pharmaceutical Industries analyst review<\/strong> is constructive for pharma investors. Consult a SEBI-registered advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Sun_Pharmas_India_business_growth\"><\/span><strong>What is Sun Pharma&#8217;s India business growth?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India branded generics grow at 10 to 12 percent YoY across chronic therapy segments, contributing approximately 35 percent of consolidated revenue per this <strong>Sun Pharmaceutical Industries analyst review<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_US_FDA_risks\"><\/span><strong>What are the key US FDA risks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>US FDA import alerts or Warning Letters at manufacturing facilities and specialty drug pricing pressure from PBMs are the primary regulatory risks in this <strong>Sun Pharmaceutical Industries analyst review<\/strong>.<\/p>\n<p><em>Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sun Pharmaceutical Industries analyst review 2026: CMP Rs 1,720, MCap Rs 4.13L Cr, PE 36.5x. US specialty pipeline, India branded generics, Ilumya growth. May 2026.<\/p>\n","protected":false},"author":26,"featured_media":87989,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-87961","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1778830385:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["76"],"rank_math_focus_keyword":["Sun Pharmaceutical Industries Analyst Review"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":["Sun Pharmaceutical Industries Analyst Review 2026: SUNPHARMA at Rs 1,720 Buy or Hold?"],"rank_math_description":["Sun Pharmaceutical Industries analyst review 2026: CMP Rs 1,720, MCap Rs 4.13L Cr, PE 36.5x. US specialty pipeline, India branded generics, Ilumya growth. May 2026."],"_thumbnail_id":["87989"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["11550"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/15112054\/Sun-Pharmaceutical-Industries-SUNPHARMA-Stock-Analyst.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/87961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=87961"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/87961\/revisions"}],"predecessor-version":[{"id":87990,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/87961\/revisions\/87990"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/87989"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=87961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=87961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=87961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}